What podcasts say about AstraZeneca
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about AstraZeneca
13 statements · 4 positive · 7 negative · 2 neutral
AstraZeneca shares remain depressed since July
“AstraZeneca shares are pretty depressed since July”
Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx SurgesListen at 1:26
AstraZeneca shares may be experiencing a modest rebound
“it could just be rebounding a little bit”
Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx SurgesListen at 1:35
AstraZeneca shares are currently depressed relative to their level since July.
“AstraZeneca shares are pretty depressed since July really”
Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx SurgesListen at 1:41
The failed trial is a slight setback for AstraZeneca.
“So, a slight setback there.”
Open the episode · Fresnillo AstraZeneca Climbs, Argenx SurgesListen at 2:02
AstraZeneca has become a cancer-drug powerhouse in recent years.
“it's become a cancer drug powerhouse under the CEO over the last few years”
Open the episode · AstraZeneca Plummets, Ryanair Rises, Clarkson JumpsListen at 1:45
AstraZeneca shares fell more than 7% that morning.
“AstraZeneca shares are actually down over 7% this morning.”
Open the episode · AstraZeneca Plummets, Ryanair Rises, Clarkson JumpsListen at 2:27
AstraZeneca reported higher-than-expected profit driven by cancer medications.
“reported higher than expected profit, boosted by its blockbuster cancer medications.”
Open the episode · Forte Bioscience Pop; Astrazeneca Reports; Paramount-Warner LatestListen at 1:58
AstraZeneca’s cancer-drug growth is offsetting pressures from lost exclusivity.
“their cancer drugs and the growth there is offsetting those pressures.”
Open the episode · AstraZeneca Climbs, Vodafone Gains, Pinewood SurgesListen at 3:52
AstraZeneca’s late-stage clinical-trial results later this year will be important.
“there's quite a few late stage clinical trial results set for later this year and those are quite key.”
Open the episode · AstraZeneca Climbs, Vodafone Gains, Pinewood SurgesListen at 4:03
AstraZeneca set a $5 billion sales target for the heart drug.
“Astra had set a $5 billion sales target for this drug.”
Open the episode · Pepsi Reports; AstraZeneca and Levi Strauss FallListen at 2:21
The trial setback will make AstraZeneca’s $5 billion sales target harder to reach.
“this stumbling block is going to make it harder for the company to reach that deal”
Open the episode · Pepsi Reports; AstraZeneca and Levi Strauss FallListen at 2:27
AstraZeneca’s trial setback may damage perceived credibility beyond lost revenue.
“some of this reaction might just be more than a loss of potential revenue but also a perceived slip in credibility”
Open the episode · Pepsi Reports; AstraZeneca and Levi Strauss FallListen at 2:37
Wainua’s trial is a strategic setback for AstraZeneca’s disease-area ambitions.
“it's also a strategic setback because AstraZeneca has been really looking to establish itself in that disease area”
Open the episode · Deutz Buy, Astrazeneca's Trial, Computacenter UpListen at 3:20
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.